Kush Parmar
CIK: 0001664281
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Entrada Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Aug 10, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect92.4K shares at avg. $7.00$647K - Aug 7, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect52.3K shares at avg. $6.85$358K - Aug 6, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect10.5K shares at avg. $7.00$73K - Jul 31, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect1.7K shares at avg. $6.85$12K - Jul 30, 2026TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect114.8K shares at avg. $6.93$795K - Jun 10, 2026TRDA
Entrada Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19K shares- - Nov 14, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect200K shares at avg. $8.80$1.8M - Jul 9, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect6.9K shares at avg. $7.50$52K - Jul 9, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect20.1K shares at avg. $7.50$151K - Jul 1, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect18.6K shares at avg. $7.12$132K - Jul 1, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect6.4K shares at avg. $7.12$46K - Jun 30, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect6.4K shares at avg. $6.81$44K - Jun 30, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect18.6K shares at avg. $6.81$127K - Jun 27, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect19.3K shares at avg. $6.91$133K - Jun 27, 2025TRDA
Entrada Therapeutics, Inc.
Sale(S)Indirect55.7K shares at avg. $6.91$385K - Jun 11, 2025TRDA
Entrada Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 92,444 | $7.00 | $647,108 | Indirect |
| Aug 7, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 52,317 | $6.85 | $358,371 | Indirect |
| Aug 6, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 10,494 | $7.00 | $73,458 | Indirect |
| Jul 31, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 1,718 | $6.85 | $11,768 | Indirect |
| Jul 30, 2026 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 114,756 | $6.93 | $795,259 | Indirect |
| Jun 10, 2026 | TRDA Entrada Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,000 | - | - | Direct |
| Nov 14, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 200,000 | $8.80 | $1,760,000 | Indirect |
| Jul 9, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 6,935 | $7.50 | $52,026 | Indirect |
| Jul 9, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 20,065 | $7.50 | $150,528 | Indirect |
| Jul 1, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 18,578 | $7.12 | $132,324 | Indirect |
| Jul 1, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 6,422 | $7.12 | $45,741 | Indirect |
| Jun 30, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 6,422 | $6.81 | $43,751 | Indirect |
| Jun 30, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 18,578 | $6.81 | $126,566 | Indirect |
| Jun 27, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 19,265 | $6.91 | $133,121 | Indirect |
| Jun 27, 2025 | TRDA Entrada Therapeutics, Inc. | Sale(S) | 55,735 | $6.91 | $385,129 | Indirect |
| Jun 11, 2025 | TRDA Entrada Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,000 | - | - | Direct |
1-16 of 16 transactions
About PARMAR KUSH
PARMAR KUSH (SEC CIK 0001664281) files insider reports with the SEC as Director of Entrada Therapeutics, Inc. (TRDA).
Signal8 holds 7 ownership filings by PARMAR KUSH, all Form 4s, filed between Jun 12, 2025 and Aug 10, 2026. Those filings report 16 transactions, from Jun 11, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on PARMAR KUSH's filings is in SAN FRANCISCO, CA.
Recent filings by PARMAR KUSH
- Aug 10, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Aug 7, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Aug 6, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Jul 31, 2026: Open-market sale of TRDA shares (Form 4, code S).
- Jul 30, 2026: Open-market sale of TRDA shares (Form 4, code S).
Other insiders filing for Entrada Therapeutics, Inc. (TRDA)
- MPM BIOVENTURES 2018, L.P., 10% Owner
- MPM BioVentures 2014, L.P., 10% Owner
- Doshi Dipal, CEO
- Dowden Nathan J, President & COO
- Sethuraman Natarajan, President, Research & Develop.
- WENTWORTH KORY JAMES, Chief Financial Officer